Biology subjects

Nicholson, L.

Publications and source records attributed to Nicholson, L..

6 recordsLinked to original sources

bioRxiv2026

Reversible m6Am methylation of snRNA by FTO controls morphine reward and tolerance without altering analgesia

Mu opioids, such as morphine, are effective analgesics, but their reward and tolerance drive opioid use disorder. A major goal is to achieve analgesia without these harmful effects. Here we show that morphine reward and tolerance require the RNA demethylase FTO. Genetic depletion and pharmacologic inhibition of FTO each reduced morphine reward, measured by conditioned-place preference, and reduced antinociceptive tolerance to morphine and fentanyl, without altering analgesia. Although FTO is known to erase m6A on mRNA, we found no effect of FTO depletion on m6A sites, but markedly increased levels of m6Am on snRNA. The effects of FTO depletion were suppressed in mice that cannot make m6Am, supporting the role of m6Am in morphine reward and tolerance. We show that FTO depletion regulates a gene expression network linked to morphine signaling. FTO inhibitors may therefore provide useful adjuvants to mu opioids in pain management and treatment of opioid use disorder.

neuroscience↗

bioRxiv2025

Axon Regeneration and Functional Recovery after Spinal Cord Injury is Enhanced by Allele-Specific ApoE Neuronal Action through LRP8

Adult CNS trauma frequently causes neuronal disconnection and persistent deficits due to failed axon regeneration. While model system screening has identified multiple candidate neural repair pathways, ApoE-LRP8 signaling is unique in being implicated clinically. Here, we show that cortical axon regeneration requires LRP8 and is modified by APOE variants. ApoE2-expressing mice show reparative corticospinal and raphespinal axon growth with greater motor function than controls after spinal cord injury. Distinct from ApoE in other settings, there is no change in inflammation or scarring. After axotomy, ApoE exerts allele-specific effects on LRP8 localization and signaling in cortical neurons. APOE alleles regulate synaptic organization gene expression by cortical neurons after injury, with little effect on glial gene expression. AAV-mediated overexpression of ApoE2 in mice after spinal trauma increases locomotor recovery and reparative axon growth. Thus, ApoE-LRP8 signaling for axon regrowth following CNS trauma provides a potential therapeutic intervention site.

neuroscience↗

bioRxiv2025

Insulin resistance alters cortical inhibitory neurons and microglia to exacerbate Alzheimer knock-in mouse phenotypes

Metabolic dysfunction contributes to the risk and progression of Alzheimer"s disease (AD) through insulin signaling, but the cellular mechanisms are not fully understood. In this study, we examined the effects of streptozotocin-induced insulin deficiency or a high-fat, high-sugar (HFHS) diet-induced insulin resistance on cognitive function in knock-in AD mouse models expressing human mutant APP and wild-type tau. Both metabolic perturbations caused hyperglycemia, but only the HFHS diet resulted in weight gain and greater learning and memory deficits. The HFHS diet exacerbation occurred without changes in amyloid-{beta} or phospho-tau accumulation and with only subtle alterations in microglial morphology. The basis for functional deficits was explored with single-nucleus transcriptomic analysis. Prominent gene expression changes in glial cells and cerebral cortex Layer 2 inhibitory neurons correlated with the enhanced behavioral deficits. In HFHS-fed AD mice, we observed a shared metabolic impairment in neurodegeneration (MinD) state across multiple glial cell types. Additionally, the HFHS diet, with or without AD pathology, induced selective upregulation of the transcription factor Meis2 in cortical Layer 2 inhibitory neurons, in association with pathways involved in cell excitability. Overall, these findings suggest that HFHS-driven metabolic stress affects brain function and behavior through specific cellular programs distinct from amyloid or tau pathology, and identifies new targets that link diet-induced metabolic stress to cognitive decline in AD.

neuroscience↗

bioRxiv2024

Decoding m6Am by simultaneous transcription-start mapping and methylation quantification

N6,2-O-dimethyladenosine (m6Am) is a modified nucleotide located at the first transcribed position in mRNA and snRNA that is essential for diverse physiological processes. m6Am mapping methods assume each gene uses a single start nucleotide. However, gene transcription usually involves multiple start sites, generating numerous 5 isoforms. Thus, gene levels annotations cannot capture the diversity of m6Am modification in the transcriptome. Here we describe CROWN-seq, which simultaneously identifies transcription-start nucleotides and quantifies m6Am stoichiometry for each 5 isoform that initiates with adenosine. Using CROWN-seq, we map the m6Am landscape in nine human cell lines. Our findings reveal that m6Am is nearly always a high stoichiometry modification, with only a small subset of cellular mRNAs showing lower m6Am stoichiometry. We find that m6Am is associated with increased transcript expression and provide evidence that m6Am may be linked to transcription initiation associated with specific promoter sequences and initiation mechanisms. These data suggest a potential new function for m6Am in influencing transcription.

molecular biology↗

bioRxiv2023

Neuronal Transcriptome Disruption, Tau Accumulation and Synapse Loss in Alzheimer's Knock-in Mice Require Cellular Prion Protein

BackgroundCellular prion protein (PrPC) is a high-affinity cell-surface receptor for Amyloid-{beta} oligomers (A{beta}o). In certain overexpression models of Alzheimers Disease (AD), pharmacology and genetics demonstrate its essential role for synaptic plasticity impairment, memory deficits and synapse loss. However, PrPCs role in AD-related phenotypes with endogenous expression levels, its role in tau accumulation and its effect on imaging biomarkers are unknown. The necessity of PrPC for transcriptomic alterations driven by A{beta} across cell types is unexplored. MethodsThe role of PrPC was examined as a function of age in homozygous AppNL-G-F/hMapt double knock-in mice (DKI). Phenotypes of AppNL-G-F/hMapt mice with a deletion of Prnp expression (DKI; Prnp-/-) were compared with DKI mice with intact Prnp, mice with a targeted deletion of Prnp (Prnp-/-), and mice with intact Prnp (WT). Phenotypes examined included behavioral deficits, synapse loss by PET imaging, synapse loss by immunohistology, tau pathology, gliosis, inflammatory markers, and snRNA-seq transcriptomic profiling. ResultsBy 9 months age, DKI mice showed learning and memory impairment, but DKI; Prnp-/- and Prnp-/- groups were indistinguishable from WT. Synapse loss in DKI brain, measured by [18F]SynVesT-1 SV2A PET or anti-SV2A immunohistology, was prevented by Prnp deletion. Accumulation of Tau phosphorylated at aa 217 and 202/205, C1q tagging of synapses, and dystrophic neurites were all increased in DKI mice but each decreased to WT levels with Prnp deletion. In contrast, astrogliosis, microgliosis and A{beta} levels were unchanged between DKI and DKI; Prnp-/- groups. Single-nuclei transcriptomics revealed differential expression in neurons and glia of DKI mice relative to WT. For DKI; Prnp-/- mice, the majority of neuronal genes differentially expressed in DKI mice were no longer significantly altered relative to WT, but most glial DKI-dependent gene expression changes persisted. The DKI-dependent neuronal genes corrected by Prnp deletion associated bioinformatically with synaptic function. Additional genes were uniquely altered only in the Prnp-/-or the DKI; Prnp-/- groups. ConclusionsA functional Prnp gene is required in AppNL-G-F/hMapt double knock-in mice for synapse loss, phospho-tau accumulation and neuronal gene expression. These data support the efficacy of targeting the A{beta}o-PrPC interaction to prevent A{beta}o-neurotoxicity and pathologic tau accumulation in AD.

neuroscience↗

bioRxiv2020

Activation of bone marrow adaptive immunity in type 2 diabetes: rescue by co-stimulation modulator Abatacept

Hypothesis Type 2 diabetes (T2D) is characterized by low-grade inflammation. Here, we investigated the state of adaptive immunity in bone marrow (BM) of patients and mice with T2D. We also tested if inhibition T cell co-stimulation by Abatacept could rescue the immune profile of T2D mice.Methods Flow-cytometry and cytokine analyses were performed on BM samples from patients with or without T2D. Moreover, we studied the immune profile of db/db and control wt/db mice. A cohort of db/db mice was randomized to receive Abatacept or vehicle for 4 weeks, with endpoints being immune cell profile and indexes of insulin sensitivity and heart performance.Results T2D patients showed increased frequencies of BM CD4+ (2.8-fold, p=0.001) and CD8+ T cells (1.8-fold, p=0.01), with upregulation of the activation marker CD69 and homing receptor CCR7 in CD4+ (1.64-fold, p=0.003 and 2.27-fold, p=0.01, respectively) and CD8+ fractions (1.79-fold, p=0.05 and 1.69-fold, p=0.02, respectively). CCL19 (CCR7 receptor ligand) and CXCL10/11 (CXCR3 receptor ligands), implicated in T cell migration and activation, were the most differentially modulated chemokines. Studies in mice confirmed the activation of adaptive immunity in T2D. Abatacept reduced the activation of T cells and levels of pro-inflammatory chemokines and cytokines. Additionally, Abatacept improved indexes of cardiac systolic function, but not insulin sensitivity.Conclusions These novel findings support the concept of BM adaptive immune activation in T2D. Modulation of T cell co-stimulation could represent an attractive and immediately available modality to dampen inappropriate activation of adaptive immune response and protect from target organ damage.Competing Interest StatementThe authors have declared no competing interest.Abbreviations(APCs)antigen-presenting cells(BM)bone marrow(BMMCs)BM mononuclear cells(CO)cardiac output(TCM)central memory(CCR7)CC-chemokine receptor 7(DCs)dendritic cells(EDV)end diastolic volume(TEM)effector memory(ND)non-diabetic control(HSPCs)hematopoietic stem/progenitor cells(SV)stroke volume(TEMRA)terminally differentiated T memory cells(T2D)type 2 diabetes mellitus(VAT)visceral adipose tissueView Full Text

immunology↗